Practical Reviews

Lu-177 PSMA Ligand Therapy Safe, Effective After Chemo in mCRPC Patients

Background: Lu-177 prostate-specific membrane antigen (PSMA) 617 is a highly promising new form of treatment for patients with metastatic prostate cancer, although there are many questions remaining to be answered about this therapy. One of those questions is how effective is this treatment in patients who have already received chemotherapy. Objective: To analyze overall survival (OS) and factors predicting longer survival in patients treated with 177Lu-PSMA-617 radioligand therapy more...
To view this content, you must be a logged in subscriber to
Please Login to view this content.